Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 12846

1.

Associating 197 Chinese herbal medicine with drug targets and diseases using the similarity ensemble approach.

Gu S, Lai LH.

Acta Pharmacol Sin. 2019 Sep 17. doi: 10.1038/s41401-019-0306-9. [Epub ahead of print]

PMID:
31530902
2.

Efficacy, Safety and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin ± Metformin in Patients with Type 2 Diabetes: the PIONEER 8 Trial.

Zinman B, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, Pedersen KB, Tarp-Johansen MJ, Araki E; PIONEER 8 investigators.

Diabetes Care. 2019 Sep 17. pii: dc190898. doi: 10.2337/dc19-0898. [Epub ahead of print]

PMID:
31530667
3.

Oral Semaglutide versus Empagliflozin in Patients with Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.

Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, Gumprecht J, Lindberg SØ, Lingvay I, Søndergaard AL, Treppendahl MB, Montanya E; PIONEER 2 investigators.

Diabetes Care. 2019 Sep 17. pii: dc190883. doi: 10.2337/dc19-0883. [Epub ahead of print]

PMID:
31530666
4.

Sitagliptin decreases visceral fat and blood glucoses in women with polycystic ovarian syndrome.

Devin JK, Nian H, Celedonio JE, Wright P, Brown NJ.

J Clin Endocrinol Metab. 2019 Sep 15. pii: dgz028. doi: 10.1210/clinem/dgz028. [Epub ahead of print]

PMID:
31529097
5.

Dipeptidyl Peptidase 4 Inhibition Increases Postprandial Norepinephrine via Substance P (NK1 Receptor) During RAAS Inhibition.

Wilson JR, Kerman SJ, Hubers SA, Yu C, Nian H, Grouzmann E, Eugster PJ, Mayfield DS, Brown NJ.

J Endocr Soc. 2019 Jul 1;3(10):1784-1798. doi: 10.1210/js.2019-00185. eCollection 2019 Oct 1.

PMID:
31528826
6.

Efficacy and safety of evogliptin versus sitagliptin as an add-on therapy in Indian patients with type 2 diabetes mellitus inadequately controlled with metformin: A 24-week randomized, double-blind, non-inferiority, EVOLUTION INDIA study.

Kumar Ajmani A, Agrawal A, Prasad BLN, Basu I, Shembalkar J, Manikanth N, Subrahmanyam KAV, Srinivasa M, Chawla M, Kumar Srivastava M, Jebasingh F, Basavprabhu A, Agrawal RP, Pulichikkat RK, Meena R, Bhatia S, Kumar Gupta S, Dange A, Srivastava A, Trailokya A, Shahavi V, Shende S.

Diabetes Res Clin Pract. 2019 Sep 14:107860. doi: 10.1016/j.diabres.2019.107860. [Epub ahead of print]

PMID:
31526825
7.

In poorly controlled type 2 diabetes, oral semaglutide was noninferior to liraglutide for reducing HbA1c.

Lipscombe LL.

Ann Intern Med. 2019 Sep 17;171(6):JC29. doi: 10.7326/ACPJ201909170-029. No abstract available.

PMID:
31525763
8.

In patients ≥ 50 years with type 2 diabetes and CV disease or risk factors, oral semaglutide did not increase CV events.

Lipscombe LL.

Ann Intern Med. 2019 Sep 17;171(6):JC28. doi: 10.7326/ACPJ201909170-028. No abstract available.

PMID:
31525762
9.

A Prospective Study on the Effect of Corticosteroid Injection Dosage for Hand Disorders in Non-Insulin Dependent Diabetics.

Lekic N, Patel AA, Friend ME, Donnally CJ, Chen DL, Askari M.

Bull Hosp Jt Dis (2013). 2018 Sep;76(3):198-202.

PMID:
31513524
10.
11.

Dipeptidyl peptidase-4 inhibitors can inhibit angiotensin converting enzyme.

Abouelkheir M, El-Metwally TH.

Eur J Pharmacol. 2019 Sep 3;862:172638. doi: 10.1016/j.ejphar.2019.172638. [Epub ahead of print]

PMID:
31491403
12.

Efficacy and hypoglycemic risk of sitagliptin in obese/overweight patients with type 2 diabetes compared with GLP-1 receptor agonists: A meta-analysis.

Dai D, Mao Y, Jin H, Zhang W.

Medicine (Baltimore). 2019 Sep;98(36):e17081. doi: 10.1097/MD.0000000000017081.

13.

[Semaglutide, once weekly GLP-1 receptor agonist (Ozempic®)].

Scheen AJ.

Rev Med Liege. 2019 Sep;74(9):488-494. French.

PMID:
31486321
15.

Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS.

Nauck MA, McGuire DK, Pieper KS, Lokhnygina Y, Strandberg TE, Riefflin A, Delibasi T, Peterson ED, White HD, Scott R, Holman RR.

Cardiovasc Diabetol. 2019 Sep 3;18(1):116. doi: 10.1186/s12933-019-0921-2.

16.

Diurnal Variation of Sitagliptin-Induced Pharmacological Effects in C57BL/6J Mice.

Yoshioka H, Hirose Y, Ohishi R, Tominaga S, Torii-Goto A, Park SJ, Miura N, Yoshikawa M.

Biol Pharm Bull. 2019;42(9):1562-1568. doi: 10.1248/bpb.b19-00367.

17.

Dipeptidyl peptidase-4 inhibitors do not alter GH/IGF-I axis in adult diabetic patients.

Teti C, Talco M, Albertelli M, Albanese V, Minuto M, Aglialoro A, Monachesi M, Viviani G, Gatto F, Ferone D, Boschetti M.

J Endocrinol Invest. 2019 Aug 31. doi: 10.1007/s40618-019-01106-6. [Epub ahead of print]

PMID:
31473983
18.

Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients with Diabetes: A Double-Blind Randomized Controlled Trial.

Lynch M, Malara A, Timoney I, Ahern T, Awdeh F, Sweeney C, Galligan M, Venckens S, Kelly G, Hughes R, O Apos Shea D, Doran P, Kirby B.

Dermatology. 2019 Aug 30:1-4. doi: 10.1159/000502130. [Epub ahead of print] No abstract available.

19.

Pharmacovigilance Assessment of Drug-Induced Acute Pancreatitis Using a Spontaneous Reporting Database.

Niinomi I, Hosohata K, Oyama S, Inada A, Wakabayashi T, Iwanaga K.

Int J Toxicol. 2019 Aug 30:1091581819870717. doi: 10.1177/1091581819870717. [Epub ahead of print]

PMID:
31470743
20.

Effects of sitagliptin on gastric emptying of, and the glycaemic and blood pressure responses to, a carbohydrate meal in type 2 diabetes.

Stevens JE, Buttfield M, Wu T, Hatzinikolas S, Pham H, Lange K, Rayner CK, Horowitz M, Jones KL.

Diabetes Obes Metab. 2019 Aug 29. doi: 10.1111/dom.13864. [Epub ahead of print]

PMID:
31468664

Supplemental Content

Loading ...
Support Center